David Mahoney Net Worth

The estimated Net Worth of David L Mahoney is at least $1.75 Milion dollars as of 10 April 2024. Mr. Mahoney owns over 30,000 units of Adamas Pharmaceuticals Inc stock worth over $246,600 and over the last 22 years he sold ADMS stock worth over $1,237,721. In addition, he makes $264,876 as Lead Independent Chairman of the Board at Adamas Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mahoney ADMS stock SEC Form 4 insiders trading

David has made over 28 trades of the Adamas Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ADMS stock worth $52,200 on 10 April 2024.

The largest trade he's ever made was buying 285,714 units of Adamas Pharmaceuticals Inc stock on 6 February 2009 worth over $197,143. On average, David trades about 17,946 units every 82 days since 2003. As of 10 April 2024 he still owns at least 30,000 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Mr. Mahoney stock trades at the bottom of the page.

David Mahoney biography

David L. Mahoney serves as Lead Independent Chairman of the Board of the Company. Mr. Mahoney has served on the board of directors of Symantec Corporation, a publicly-traded software technology company since 2003, including as current chair of the Compensation and as former chair of the Nominating and Governance Committees. Mr. Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011. Mr. Mahoney has served on the board of directors of Corcept Therapeutics Incorporated, a pharmaceutical company since 2004, including as a member of the Audit and as a chair of the Nominating and Governance Committees. He also serves on the boards of directors of San Francisco Museum of Modern Art, Mount Holyoke College and Mercy Corps, and is a Trustee of the Schwab/Laudus Family of Funds. From 1999 to 2001, Mr. Mahoney served as co-CEO of McKesson HBOC, Inc., a healthcare supply management and information technology company and as CEO of McKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney holds a B.A. from Princeton University and an M.B.A. from Harvard University.

What is the salary of David Mahoney?

As the Lead Independent Chairman of the Board of Adamas Pharmaceuticals Inc, the total compensation of David Mahoney at Adamas Pharmaceuticals Inc is $264,876. There are 3 executives at Adamas Pharmaceuticals Inc getting paid more, with Neil McFarlane having the highest compensation of $2,080,640.

How old is David Mahoney?

David Mahoney is 65, he's been the Lead Independent Chairman of the Board of Adamas Pharmaceuticals Inc since 2019. There are 2 older and 10 younger executives at Adamas Pharmaceuticals Inc. The oldest executive at Adamas Pharmaceuticals Inc is Ivan Lieberburg, 70, who is the Independent Director.

What's David Mahoney's mailing address?

David's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney oraz William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Mr. Mahoney stock trades at Adamas Pharmaceuticals Inc i Corcept Therapeutics Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director